ICEECE2012 Poster Presentations Endocrine tumours and neoplasia (112 abstracts)
Efficacy of Everolimus to prevent hypoglycemia in patients with metastatic insulinomas: for the French group of endocrine tumors (GTE-Renaten)
V. Bernard 1 , C. Lombard-Bohas 2 , B. Goichot 3 , V. Rohmer 4 , R. Guimbaud 5 , P. Niccoli 5 , C. Chougnet 1 , P. Ruszniewski 7 & E. Baudin 1
Hôpital Beaujon, Clichy, France.
Background: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and everolimus could be a new therapeutic option.
Methods: We conducted a restrospective multicentric study within the French group of endocrine tumors to evaluate the time to first symptomatic recurrence (TSR) in patients with RHMI after everolimus initiation. Ongoing hyperglycemic medical options and safety were recorded.
Results: Twelve patients with RHMI treated with everolimus (dose initiation: 10mg/d except one patient 5mg/d) between May 2007 and June 2011 were reviewed. Everolimus was given after a median of four previous therapeutic lines and median duration was 6.5 months (range, 1.5–32+= ongoing months). Clinical benefits were observed in eleven patients. Median TSR was 6.5 months (range, 0–32+ months): 7 and 5 patients remained symptom free for more than 3 and 6 months respectively. 5 patients were still treated at 6, 7, 10, 12 and 32+months. Six patients discontinued additional hyperglycemic therapies including three glucose infusions. Three patients discontinued everolimus because of pulmonary side effects at 1.5, 3 and 7 months of initiation: two deaths occurred (one non-infectious pneumonitis and one pneumocistis pneumonia). Three patients discontinued everolimus because of disease progression at 2, 3 and 10 months of initiation, without hypoglycemia recurrence.
Conclusion: Everolimus appears as a new effective treatment modality for metastatic insulinomas complaining of refractory hypoglycemia. Pulmonary tolerance should be carefully monitored.
Declaration of interest: I fully declare a conflict of interest. Details below.
Funding: This work was supported, however funding details unavailable.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more